CNIC-Polypill (n = 1614) | Monocomponents (n = 1614) | Equipotent (n = 1614) | Other Therapies (n = 1614) | |
---|---|---|---|---|
Difference between baseline and study end | ||||
Lipid profile, mg/dL, mean (SD) | ||||
Total cholesterol, | –54.9 (43.2)* | –42.8 (45.2)* † | –31.7 (43.3)* † | –31.7 (42.4)* † |
LDL cholesterol, | –19.6 (38.2)* | –12.9 (42.2)* ‡ | –12.3 (39.7)* † | –9.1 (41.2)* † |
HDL cholesterol, | 6.5 (10.2)* | 4.6 (10.5)* † | 3.8 (11.0)*‡ | 2.8 (11.0)* |
Triglycerides | –67.5 (98.7)* | –59.9 (80.3)* ‡ | –56.1 (77.1)* † | –54.4 (79.5)* † |
Blood pressure, mm Hg, mean (SD) | ||||
SBP | –14.1 (24.8)* | –11.7 (23.9)* ‡ | –10.4 (24.3)* † | –10.4 (23.6)* † |
DBP | –4.5 (13.3)* | –2.5 (12.0)* † | –2.1 (12.4)* † | –1.2 (12.7)* † |
Patients with CVRF control at the study end, % | ||||
LDL-c < 70 mg/dL | 15.4* | 12.5* † | 12.8* † | 11.6 † |
Triglycerides < 150 mg/dL | 50.9* | 43.4* † | 42.3* † | 40.7* † |
SBP < 130/80 mm Hg | 44.1* | 37.9*, ** | 34.6‡ | 32.4‡ |